IOPM, FNET, SCII, GETG, FMNJ, VTRO OTCPicks.com Stocks to Watch for Wednesday, September 16th

Our Stocks to Watch tomorrow IntraOp Medical Corp. (OTCBB: IOPM), FortuNet Inc. (Nasdaq: FNET), Stem Cell Therapy International Inc. (OTCBB: SCII), Green Earth Technologies Inc. (OTC: GETG), Franklin Mining Inc. (OTC: FMNJ) and Vertro, Inc. (Nasdaq: VTRO).

 

Visit http://www.otcpicks.com/microcap.htm today to join this growing community.

 

INTRAOP MEDICAL CORPORATION (OTCBB: IOPM)

"Up 315.79% on Tuesday"

 

Detailed Quote: www.otcpicks.com/quotes/IOPM.php 

 

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively — for all cancer patients. The company’s flagship product, the Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, immediate palliative effect, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics world-wide are increasingly using the Mobetron to treat a wide variety of cancers as a vital part of their comprehensive cancer program.

 

IOPM News:

 

September 15 - Groundbreaking Breast Cancer Radiation Technique Delivers Proven Long-Term Benefits and Saves Lives

 

One minute of radiation in the operating room (OR) could save the lives of thousands of women being treated for breast cancer in the US today. According to a growing body of research, a 60-second course of radiation therapy delivered during surgery dramatically improves results. But, until recently, logistical and administrative difficulties prevented most patients from receiving this crucial treatment until weeks after their procedures.

 

Now, a portable, self-contained radiation therapy system, the Mobetron from IntraOp Medical Corporation (OTCBB: IOPM) in Sunnyvale, Calif., is changing all that. St. Joseph Hospital (Orange, Calif.), one of only 16 prestigious designated National Cancer Institute Community Cancer Centers, this month introduced the first ongoing intraoperative electron radiation therapy (IOERT) program for breast cancer. During lumpectomy surgery, St. Joseph’s patients receive a high dose of therapy focused specifically on the tumor site, known as a “boost.” Given the benefits, other facilities are expected to follow suit.

 

Felix Sedlmayer, MD, one of the world’s leading IOERT researchers and the principal investigator of IOERT boost trials conducted by six European medical centers over the past decade, concluded that IOERT cut breast cancer five year recurrence rates dramatically, from an average of 5% to less than 1%.

 

“If the IOERT boost were a standard technique in the US, every year, more than 5000 breast cancer recurrences could have be avoided,” according to Roland Reitsamer, MD, a surgeon at the University of Salzburg, where the technique has been studied extensively for the past decade. Each one of those recurrences typically would result in a subsequent mastectomy, which also would be avoided. A prestigious Lancet review of studies on breast cancer found a 25% increase in 15 year survival for patients with no recurrences at five years, suggesting that IOERT boost could have a significant impact on the survival of thousands of women worldwide.

 

What Every Woman Should Know About Intraoperative Radiation

 

It seems a matter of common sense. Lumpectomy is typically followed by a six-week course of radiation therapy to help eliminate any remaining malignant cells. Treatment takes place at least four weeks after surgery when the breast has healed. Because traditional, post-operative radiation is delivered externally, it must pass through the body to reach diseased areas, and healthy tissue may be damaged in the process. Additionally, once surgery is complete, physicians no longer have direct access to the target area to easily and precisely deliver radiation.

 

So why not begin the radiation treatment during the surgery itself? This would immediately target any remaining cancer cells, while allowing complete access to the tumor area for greater precision in radiation delivery. It also would spare radiation dose to surrounding tissue and reduce the number of days a woman has to travel to a cancer center for external treatment after surgery. In fact, at St. Joseph, IOERT will shorten the course of post-operative radiation by seven to 10 days by delivering the targeted boost dose prior to, rather than after, traditional treatments.

 

“The answer is that intraoperative radiation simply hasn’t been practical until now,” explains John Powers, CEO for IntraOp. ”Without the Mobetron, the treatment would mean equipping a special operating room with a costly, unwieldy 18,000 pound linear accelerator to generate radiation as well as a shielded radiation vault to protect staff from repeated exposure to this radiation. This is just not feasible for most hospitals.”

 

The other alternative, Mr. Powers points out, has been transferring patients under anesthesia with an open incision from the OR to a radiation therapy center, typically located offsite. This significantly increases the risk and duration of surgery and anesthesia. The result: despite its enormous benefits, IOERT has rarely been used in the US for breast patients.

 

However, IOERT has been heavily investigated in major European university hospitals and is currently in use in more than a dozen facilities. This is not surprising because historically the European medical system has been an early adopter of promising new paradigms for breast cancer diagnosis and treatment, including mammography, breast conserving lumpectomy and sentinel node biopsy.

 

The Mobetron

 

Specifically optimized for IOERT, the IntraOp Mobetron incorporates a range of technological innovations to make all the benefits of this treatment realistic and practical for women and their doctors around the world. The innovative system eliminates the risk, time, cost and complexity of IOERT by enabling delivery in any standard OR.

 

Unlike conventional linear accelerators, the Mobetron is relatively lightweight and can be wheeled among different OR locations. The Mobetron requires no external radiation vault or bunker because patented technologies eliminate most stray room radiation generated by conventional accelerators and because of its patented self-shielding,

 

To operate the device, following tumor excision, a Mobetron applicator tube is temporarily inserted into the breast to provide precise treatment directly to the tumor bed. The Mobetron is positioned for radiation delivery, and the one-minute treatment takes place.

 

FORTUNET INCORPORATED (NASDAQ: FNET)

"Up 96.00% on Tuesday"

 

Detailed Quote: http://www.otcpicks.com/quotes/FNET.php

 

FortuNet, Inc., together with its subsidiaries, engages in the design, manufacture, field maintenance, and leasing of electronic gaming and entertainment systems in North America. It offers wireless and stationary player terminals, cashier-based point-of-sale terminals, self-service kiosks, and game file servers that conduct and control bingo games. The company also provides player tracking, accounting, and inventory management, as well as reporting software package that analyzes and reports players’ spending and automatically issues electronic coupons that provide players with incentives to play multiple bingo sessions; gaming software package that executes on multi-game and multi-player gaming platforms, as well as provides various downloadable traditional casino games; and radio frequency communication hardware and software for wireless communications. Its platforms are also adapted to conduct traditional casino games, such as keno, poker, and slots. The company owns and leases an inventory of third- and fourth-generation wireless and stationary player terminals marketed under the BingoStar brand name. In addition, FortuNet, Inc. offers consumable bingo products, smart bingo flashboards, and ball blowers. It serves bingo hall operators in the commercial casino, tribal casino, and charitable bingo markets. The company distributes its products through indirect channels and a network of distributors in the United States, Canada, the United Kingdom, and Australia. FortuNet, Inc. was founded in 1989 and is based in Las Vegas, Nevada.

 

FNET News:

 

August 13 - FortuNet Reports Second Quarter 2009 Results

 

FortuNet, Inc. (Nasdaq: FNET) (the "Company") filed with the Securities and Exchange Commission (SEC) its quarterly report on Form 10-Q for the quarter ended June 30, 2009.

 

The Company's revenue decreased during the quarter as compared to the same quarter in the prior year. Specifically, for the quarter ended June 30, 2009 the sales were $3.96 million as compared with the sales of $3.97 million for the same quarter of last year, a decrease of approximately 0.3%. The earnings per share for the current quarter are 5 cents, compared to 8 cents for the same quarter of the previous year, a decrease of 37.5%.

 

STEM CELL THERAPY INTERNATIONAL (OTCBB: SCII)

"Up 85.00% on Tuesday"

 

Detailed Quote: http://www.otcpicks.com/quotes/SCII.php

 

Stem Cell Therapy International, Inc., through its wholly owned subsidiary, Stem Cell Therapy International Corp., engages in licensing of stem cell technology and the sale of stem cell products, as well as the provision of information, education, and referral services. It provides allo stem cell biological solutions that are used in the treatment of patients suffering from degenerative disorders of the human body, such as Alzheimer's Disease, Parkinson's Disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, and diabetes, as well as certain types of cancer. The company's stem cell biological solutions can be used to alleviate the side effects of chemotherapy. Its principal stem cell products are solutions containing allo stem cell biological solutions, either adult stem cells, and stem cells that are extracted from umbilical cord blood. It intends to offer biological solutions containing stem cell products primarily in the United States to universities, institutes, and privately funded laboratory facilities for research purposes and clinical trials. The company was incorporated in 2004 and is headquartered in Tampa, Florida.

 

SCII News:

 

September 10 - Stem Cell Therapy International Inc. Announces Histostem Litigation Settlement

 

Stem Cell Therapy International Has Agreed to Be a Party to the Settlement; Settlement Requires Histostem and Stem Cell Therapy International Inc. to Merge

 

Stem Cell Therapy International Inc. (OTCBB: SCII) announced that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.

 

For the consideration provided by Histostem USA, including but not limited to a waiver of claims and a general release, Histostem Korea and SCII have agreed to pay Histostem USA $100,000 in cash, which will be divided into three equal payments over a two year period; and seven and one half percent (7.50%) of the fully diluted total outstanding shares of SCII common stock following the close of the merger between Histostem Korea and SCII. The management of Stem Cell Therapy International, Inc. will continue to finalize a new merger agreement between SCII and Histostem Korea in the next fifteen days.

 

Andrew J. Norstrud, Chief Financial Officer, states, "Over the past year, it has been very challenging to make significant progress in operations, obtain the necessary financing to execute our global strategy and complete the merger while we were waiting for the final resolution in the Histostem Korea litigation." Mr. Norstrud also stated, "We appreciate all of the investors that have continued to support SCII and we look forward to completing this merger and obtaining the necessary financing to enable us to accelerate our strategic initiatives in the near future."

 

The Company plans to leverage Histostem Korea's technology to be the state-of-the-art conduit for bringing Asian adult stem cells into the U.S. for clinical trials and the treatment of conditions on which Americans spend billions of dollars annually. This is predicated on successful clinical trial results by Histostem Korea for Male Pattern Baldness, Buerger's Disease and other conditions, whose repository of over 80,000 cord blood units has consistently met the rigorous standards of the Korean FDA. This has made Histostem Korea the largest repository of cord blood in the world, and one of the first to actually profit from sales of its own stem cell-derived products.

 

ABOUT AMSTEM INTERNATIONAL, INC.

 

AmStem International, Inc. is a wholly owned subsidiary of SCII, and a new biotechnology company based in Northern California, in the watershed of stem cell innovation fueled by President Obama's recent announcement to lift Federal funding limitations for stem cell research. AmStem provides biotherapeutic and cosmetic stem cell products, stem cell collection and storage know-how, and access to nanotechnology vital to cutting edge stem cell research. Further information about AmStem International, Inc. can be found by contacting David Stark, SCII President, at the email posted below.

 

ABOUT HISTOSTEM CORPORATION, LTD.

 

Histostem Corp., Ltd. started in Seoul, Korea in 2000. To date it has treated more than 500 patients with stem cells and currently has 56 full-time employees and 28 part-time employees. Histostem's intellectual property portfolio consists of five patents that have been granted and six patents pending. To its knowledge Histostem is one of the very few stem cell companies in the world currently earning several million dollars in income from its products and technology. Further information about Histostem Corporation, Ltd. can be found by contacting David Stark, SCII President, at the email posted below.

 

GREEN EARTH TECHNOLOGIES INCORPORATED (OTC: GETG)

"Up 50.00% in Tuesday"

 

Detailed Quote: http://www.otcpicks.com/quotes/GETG.php 

 

Green Earth Technologies produces G-branded superior performing totally green products made with American-grown base oils that utilize the power of nanotechnology to deliver environmentally friendly products with no compromise, meaning consumers can now "do their part" without having to give up performance or value: Save the Earth — Sacrifice Nothing. The G-brand family of products include G-OIL™, G-LUBE™, G-WASH™, G-GLASS™, G-CLEAN™, G-SCENT™, G-WHEEL™, G-PROTECT™ and G-TIRE™, and are offered in a wide range of automotive categories including performance and appearance chemicals. GET products are now available at The Home Depot, Kroger, VIP, National Auto, Fred Meyer, Joe's, participating ACE & True Value dealers, Redners, Trader Horns, The Andersons, Biggs, Bennett Auto, Frank's Auto Supermarket and Amazon.com.

 

GETG News:

 

July 29 - Green Earth Technologies Reports Nine Month Results

 

Green Earth Technologies Inc. (OTC: GETG) announced that revenues for the nine months ending March 31, 2009 totaled $2.2 million. Sales of the Company's products including bio-based and bio-degradable performance and appearance products for the home, lawn care and automotive markets commenced in March 2008, with additional product lines being introduced to the marketplace. Adjusted EBITDA loss for the nine months ending March 31, 2009 was $4.7 million which covers costs for research and development and cost for testing G-OIL® SAE 5W-30 motor oil to apply for the American Petroleum Institute (API) certification, which was achieved in March 2009, becoming the first and only bio-based motor oil to receive such distinguished honors.

 

Key accomplishments for the nine months ending March 2009 include:

 

* G-OIL® motor oil was named the official oil of the American Le Mans Series.

 

* We obtained the SM rating from API for our G-OIL(®) 4-Cycle lubricant and the API "Donut" service symbol for the SAE 5W-30 weight of our ultimate biodegradable green motor oil. We believe we are the only bio-based motor oil to receive these designations.

 

* We established a worldwide distribution agreement with Techtronics Industries Inc., which is now our largest customer, including G-OIL®, bar and chain lubricants and G-CLEAN™ biodegradable detergents.

 

* We introduced G-CLEAN "ultimate biodegradable" dissolvable detergent pressure wash pouches which are now exclusively available at The Home Depot. Just one 1.5 oz dissolvable detergent pouch has the cleaning power of a full gallon of concentrated pressure washing cleaners.

 

* Through a licensing deal with TTI, G-CLEAN Injector was specifically made to be used with all pressure washers, allowing detergent to "go through" the pump, lubricating it while cleaning @ 4,000 PSI.

 

* We formed strategic relationships with two suppliers, Bio Tec and Inventek, to produce "G"-Branded performance and appearance line of products. The partnership also outlined exclusive licensing agreements with respect to those products.

 

* We formed a strategic relationship with KPP and Olympic Oil Ltd. for bottling, packaging and other services.

 

* We entered into a sales and marketing agreement with Marketiquette to develop a sales and marketing strategy which is currently being applied to our business model.

 

* We launched a sales and marketing program utilizing product and corporate branding, promotional and advertising campaigns, point of purchase marketing, push-pull strategy, and public promotions..

 

* Our G-OIL® achieved the highest biodegradability ranking - Ultimate Biodegradable -- as determined by ASTM Standards (2.1 ASTM D-5864).

 

* We signed master distribution agreements with Steel City Products, Do Cut Sales and Service, Rotary Corporation and Sustainable Earth Products International, Ltd., securing distribution in the United States, Canada, New Zealand and certain Caribbean Islands.

 

Jeff Marshall, Chairman and CEO of Green Earth Technologies stated, "We have embarked on creating a powerful consumer brand which is becoming top of mind for consumers seeking products that are both green and effective. Our current product lines focus on categories considered to be among the biggest contributors to environmental damage and are combating these issues with innovative technology and bio-degradable performance. This will have an immediate positive impact whereby lowering carbon emissions and lessening the pollution of our land and waterways."

 

"I am confident that Green Earth Technologies will quickly develop marketing and product initiatives that will lead to significant revenue increases in an addressable global market of over $200 billion" added Jeff Loch, Founder and Chief Marketing Officer of Green Earth Technologies. "We could not be more excited about G-OIL SAE 5W-30 being awarded API certification and we have started production at an accelerated pace and expect to produce predictable quarter-over-quarter revenue growth and steady progress toward profitability."

 

For the nine months ending March 31, 2009, the Company reported net sales of approximately $2.2 million. As mentioned above, sales of the Company's products commenced only in March 2008. Net loss was $10.4 million, or ($0.14) per share which includes $5.1 million, or ($0.07) per share, in non cash stock-based compensation. The common shares and stock options were issued in exchange for royalty-free licenses and exclusivity rights, patents, certain intellectual property and for services and compensation to various parties, including employees and non-employees.

 

At March 31, 2009, cash and cash equivalents totaled $2.1 million, inventory totaled $2.2 million and total stockholders' equity was $4.3 million. During the year the Company did not capitalize any costs for research and development or costs for testing its motor oils.

 

FRANKLIN MINING INCORPORATED (OTC: FMNJ)

"Up 100.00% on Tuesday"

 

Detailed Quote: http://www.otcpicks.com/quotes/FMNJ.php

 

Franklin Mining, Inc. has mining and energy interests in the United States and Bolivia as well as energy interests in Argentina. Franklin Oil & Gas, Inc. and Franklin Mining, Bolivia are wholly owned subsidiaries. Franklin Mining, Inc. holds 51% ownership in both Franklin Oil & Gas, Bolivia S.A. and Franklin Oil & Gas International S.A. Visit www.FranklinMining.com for more information.

 

FMNJ News:

 

August 12 - Franklin Mining Announces Removal of Caveat Emptor by PinkSheets.com

 

Franklin Mining, Inc. (OTC: FMNJ) (Frankfurt: FMJ) Chairman William Petty announced that Issuer Services at Pink OTC Markets, Inc. has removed the caveat emptor warning previously assigned to the Company's listing at www.pinksheets.com.

 

The Company has published its 2008 Annual Report and First Quarter 2009 financial statements and released their accompanying Attorney's Letter with Respect to Current Information.

 

The Company's Information and Disclosure Statement was also published as of June 30, 2009 and is now available at www.pinksheets.com.

 

VERTRO INCORPORATED (NASDAQ: VTRO)

"Up 68.57% on Tuesday"

 

Detailed Quote: www.otcpicks.com/quotes/VTRO.php 

 

Vertro, Inc. (Nasdaq: VTRO) is a software and technology company that owns and operates the ALOT product portfolio. ALOT's products are designed to 'Make the Internet Easy' by enhancing the way consumers engage with content online. Through ALOT, Internet users can discover best-of-the-web third party content and display that content through customizable toolbar, homepage and desktop products. ALOT has millions of live users across its product portfolio. Together these users conduct high-volumes of type-in search queries, which are monetized through third-party search and content agreements.

 

VTRO News:

 

September 10 - Vertro, Inc. Issues Interim Update for Third Quarter 2009

 

Vertro, Inc. (Nasdaq: VTRO) provided an interim update for third quarter 2009.

 

“We believe that because certain metrics across our business improved late in the second quarter, it is important that we provide our investors, customers and other stakeholders with an update for the first two months of the third quarter,” said Peter Corrao, Vertro’s President and Chief Executive Officer.

 

Key metrics for July and August 2009 for continued operations:

 

Unless otherwise noted, results are based on the first two months of the third quarter 2009 compared to full second quarter 2009 results.

 

* Revenue for July and August 2009 of approximately $4.8 million1, compared to second quarter 2009 revenue of $6.0 million;

* Advertising spend for July and August 2009 of approximately $4.0 million, compared with second quarter 2009 advertising spend of $5.8 million;

* Operating expenses, excluding advertising spend, of approximately $2.0 million for July and August 2009, in line with expectations;

* 5.1 million live toolbar users on August 31, 2009, compared to 4.7 million on June 30, 20092;

* 4.3 million unique ALOT Home users in August 2009, compared to 2.7 million in June 20093; and

* 72.4 million searches conducted across our product portfolio in August 20094, compared to 58.4 million in June 2009.

 

“In the first two months of the third quarter we have increased live users, search volumes and monthly revenue while keeping our monthly operating expenses consistent with the second quarter. We believe that these metrics validate our growth strategy and will provide the foundations for us to achieve EBITDA profitability in the fourth quarter of 2009.”

 

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

 

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

 

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

 

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

 

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.

 

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

 

Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release.